

Improving Pregnancy Outcomes: The Challenge of Prematurity

Geeta K. Swamy, MD Duke Maternal Fetal Medicine



Preterm Birth: A Global Issue





Estimated preterm birth rates by country for the year 2010



Lancet 2012: 379: 2162-72



Visit marchofdimes.com/reportcard for an interactive version of this map.



Preterm Birth: Trends in in the US





Source: CDC/NCHS, National Vital Statistics System

Preterm Birth: Short-term Morbidity & Mortality by Gestational Age





Natl Vital Stat Rep. 2006;54(16):1-29. Figure adapted with permission Mercer BM. ObGyn 2003;101(1):178-193.

Preterm birth: Long-term Effects

- Childhood sequelae
 - Chronic lung disease
 - Visual and hearing impairments
 - Neurodevelopmental disabilities
- Adolescent & adult sequelae
 - Increased mortality risk
 - Reduced reproductive capacity/potential
 - Increased risk for psychiatric conditions



Preterm Birth is an unusual . . .



- Disease?
- Syndrome?
- Health Outcome?
- Condition defined by time rather than a distinct clinical phenotype



Risk factors for Preterm Birth



Lifestyle-Societal factors

Inadequate prenatal care Tobacco, alcohol, illicit substances Domestic violence Poor social support Psychosocial stress Excessive work hours Low socioeconomic status Short inter-pregnancy interval Environmental exposures



Medical risk factors: Hypertension Diabetes Clotting disorders Extremes of maternal weight Genitourinary Infections Fetal congenital anomalies Vaginal bleeding Prior preterm birth/poor outcome Multiple gestation Uterine/cervical anomalies Decreased cervical length

<u>Host factors</u> Extremes of maternal age Minority race Hereditary trait



Preterm Birth Phenotype









JM Moutquin – BJOG, 2003

Multifactorial Etiology of Preterm Birth



Phenotypic components of preterm birth



Interventions to Reduce Preterm Birth



- Primary directed to all women
- Secondary aimed at eliminating or reducing existing risk
- Tertiary aimed at improving outcomes in preterm infants



Tertiary Interventions for women with immediate risk of preterm birth

- Regionalized care
- Antenatal corticosteroids
- Tocolytic agents
- Antibiotics
 - PPROM latency
 - GBS prophylaxis
- Magnesium sulfate for CP prophylaxis
- While these measures have reduced perinatal morbidity and mortality, they have had no significant impact on preterm birth incidence

UukeMedicine



Secondary prevention for women at risk for preterm birth



- Prevention of indicated preterm birth
 - Low dose aspirin, calcium supplementation
- Modified maternal activity
- Nutritional supplementation
- Improved prenatal care
- Antibiotics
- Cervical cerclage
- Cervico-Vaginal Pessary
- Progesterone



Secondary prevention for women at risk for preterm birth





Progesterone use in singleton gestation with history of spontaneous PTB



Author	Ν	Primary Outcome	Intervention	Delay in Delivery	Improved Infant outcome
Meis	463	PTB < 37wks	17-OHP from 16 - 36 wks	Yes	Yes
Fonseca	142	PTB < 37wks	Vaginal progesterone 24 - 34 wks	Yes	Unclear
O'Brien	659	PTB < 32wks	Vaginal progesterone 18 – 37 wks	No	No



Meis, NEJM 2003 Jun 12;348(24):2379-85 Fonseca, AJOG 2003 Feb;188(2):419-24 O'Brien, Ultrasound ObGyn 2007 Oct;30(5):687-96

Effectiveness of Progesterone in women with prior sPTB



- 5-6 women need to be treated to prevent 1 birth <37 weeks
- 12 women need to be treated to prevent 1 birth <32 weeks





Primary prevention during pregnancy

- Primary directed to all women
- Nutritional supplementation
- Smoking cessation
- Periodontal care
- Screening-treatment
 - Benefit in cancer and cardiovascular disease
 - Involves decades of effort through education and public policy built on sound science
 - Cervical length
 - Maternal serum proteomic profiling



Relative Risk of sPTB < 35 wks by cervical length at 24 wks



lams et al, NEJM 1996

Progesterone for Short cervix



Author	Ν	Primary Outcome	Intervention	Delay in Delivery	Improved Infant outcome
Fonseca	250 CL 15mm	PTB < 34wks	Vaginal progesterone 24 – 34 wks	Yes	+/-
Hassan	458 CL 10-20mm	PTB < 33 wks	Vaginal progesterone 20 – 36 wks	Yes	Yes
Grobman	657 CL 30mm	PTB < 37wks	17-OHP 16 - 36 wks	No	No



Fonseca, NEJM 2007 Hassan, Ultrasound Obstet Gynecol 2011 Grobman, AJOG 2012

Maternal Serum Proteomics



- Secondary analysis of Preterm Prediction Study for validation of biomarker + novel proteomics for sPTB prediction
- Samples selected from 160 asymptomatic participants
 - 24 and 28 weeks 40 spontaneous PTB, 40 term births
- 3 peptides from inter-alpha-trypsin inhibitor heavy chain (ITIH)-4 protein were significantly reduced in women having subsequent sPTB
- Predictive value at 28 weeks

Measure	Sensitivity	Specificity
Single ITIH-4 peptide	65%	82.5%
ITIH-4 peptides + 6 biomarkers	86.5%	80.6%
Cervix length < 25mm	49.5%	86.8%



Esplin AJOG 2011 Iams, NEJM 1996

Proteomic Assessment of Preterm Birth (PAPR)

- Sera Prognostics, Inc.
- Observational cohort study n = 4000
- Proteomic profiles comparison of women who deliver preterm and term
- Inclusion Criteria 18+ years of age, singleton gestation, no known fetal congenital anomalies
- Estimated Study Completion Date: April 2013



Sera Prognostics, Inc. NCT01371019



Summary

- Preterm birth is complex, multifactorial, and affected by host, societal, and environmental factors
- Despite intensive research efforts, our increased knowledge of the disease process and etiology has not translated into effective strategies for disease reduction
- Significant impact on prematurity prevention can only occur with advances in primary and secondary interventions



Integrated approach to research & implementation to promote healthy pregnancy & reduce PTB and stillbirth





developing and implementing effective population-specific interventions and to promote rational health care policies. In turn, evaluation of effective interventions will further facilitate research into pathways, mechanisms, and identification of unique populations at risk.

Gravett. Strategic investments to reduce preterm birth. Am J Obstet Gynecol 2012.





